News

The results of Geneia’s year-long study – a savings of $8,375 per patient and a slowing of disease progression – demonstrate that remote patient monitoring is a wise investment for payers.

Awareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study.

A new Express Scripts report highlights risk reporting gaps and offers advice for plans looking to close those gaps to ensure accurate risk payments

Research by Express Scripts presented at the AMCP examines costs among Medicaid members in the Florida plan to members in a similar Medicaid plan without a state-mandated formulary.

After Gilead received FDA approval for a new drug for chronic hepatitis B virus (HBV), it said low-cost, generic versions would also soon be available. That is good news for Gilead, which has been targeted by Congressional representatives for the high cost of Sovaldi and Harvoni hepatitis C treatments.

FDA granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris, Seattle Genetics) to treat patients with the most common subtypes of lymphoma.

In this commentary, Gerard J. Wedig of Simon Business School discusses the many possible implications of a Trump presidency.

Study examines the effectiveness of the Walgreens Connected Care CF program compared to a matched sample of control patients.

ACA repeal/replace was a Congressional Republican cornerstone, so there will be lots of pressure to move quickly. But that may be easier said than done.

A new report highlights the highest uninsured rates by state. Is your state among the top 10?

Healthcare industry leaders and policy analysts discuss how the election results could impact healthcare.

Failure to report accurate data can result in significant penalties for Medicaid managed care plans.

Most Americans have health insurance today, but according to new research from Xerox, only three out of 10 are very confident that their current health plan is the best fit for their family.

U.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion-the latest in concerns over insulin prices.

Industry leaders share their go-to strategies.

PwC report finds most primary care teams not designed to optimize care. Here’s how to mobilize non-physicians to create a care dream team.

Alcohol and drug dependency treatment goals can tied to an insurer’s pay-for-performance incentive program. Here’s how.

Lay the groundwork for bundled payment; here are three areas in which technology can play a role.

Here’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care.

How to really understand patient experience and improve outcomes. Here are five tips to help you create a culture of excellence.

Here are some of the latest precision medicine approaches being used by managed care organizations, health systems and academic medical centers across the U.S.

As the industry moves toward value-based care, medical education must keep pace.

After carefully considering its promise and consulting with experts, Independence Blue Cross this year became the first major insurer to provide coverage for certain members who are seeking access to whole genome sequencing.

The Leapfrog Group recently released its latest hospital safety grades, and they indicate some interesting trends on a state-by-state basis.

Health plans are using advanced analytics to improve physician engagement,performance and satisfaction in ACOs and risk-sharing contracts.

The Cancer MoonShot 2020 program brings together stakeholders from pharma, community and academic oncology, as well as government and scientific communities in an effort to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients.

Drugs will be provided to health plan members on clinical trials free of charge.

In a big move for patients who take blood pressure medication on a regular basis, FDA last week approved the first generic versions of 4 drugs that contain the blood pressure-lowering medication olmesartan medoxomil (Benicar, Daiichi Sankyo).